Tyrosine News and Research

RSS

Scientists identify importance of novel protein-regulating mechanism

For years, science has generally considered the phosphorylation of proteins -- the insertion of a phosphorous group into a protein that turns it on or off -- as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death. Now, scientists from the Florida campus of The Scripps Research Institute have identified the importance of a novel protein-regulating mechanism -- called sulfenylation -- that is similar to phosphorylation and may, in fact, open up opportunities to develop new types of drugs for diseases such as cancer.

12 Dec 2011

PCI-32765 is highly active and well tolerated in patients with CLL

An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

12 Dec 2011

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Ixabepilone-sunitinib combination holds potential against chemotherapy-resistant ovarian cancer

The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.

8 Dec 2011

Study shows new biochemical disturbances in the brains of children with ADHD

A new study at örebro University in Sweden shows that children with ADHD have nearly 50 percent less of a protein that is important for attention and learning. The finding may mean that there are other biochemical disturbances in the brains of individuals with ADHD than was previously believed.

5 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Lapatinib could extend survival in women with Her2-positive breast cancer

Treatment with lapatinib could extend survival in women with Her2-positive breast cancer that has spread to the brain, according to research published in the British Journal of Cancer.

30 Nov 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011

Scientists identify factors that lead to concomitant tumor resistance

Scientists are another step closer to understanding what drives tumor metastasis, as laboratory models suggest there are factors inside tumors that can slow their own growth.

14 Nov 2011

Health supplement hope for child muscle disease

A health supplement used by bodybuilders could be the key to treating a life-threatening muscular dystrophy affecting hundreds of Australian children, new research shows.

14 Nov 2011

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

11 Nov 2011

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML), inotuzumab in non-Hodgkin lymphoma (NHL), as well as the first presentation of clinical data for PF-04449913, which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

Phase 1 clinical studies of the experimental anticancer drug lenvatinib indicate that it may achieve at least a partial response in thyroid, endometrial, and renal cancers and melanoma.

28 Oct 2011

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

BeiGene, Ltd., today announced that it has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV and its affiliates for two clinical-stage oncology compounds.

15 Oct 2011

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers - combine them with inhibitors of the MEK/ERK signaling pathway.

11 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

Fat-rich 'western diet' fuels cardiovascular disease, type 2 diabetes and obesity

A major risk factor for cardiovascular disease, type 2 diabetes and other health- and life-threatening conditions, obesity is epidemic in the United States and other developed nations where it's fueled in large part by excessive consumption of a fat-rich "Western diet."

30 Sep 2011

Tyrosine News and Research

Scientists identify importance of novel protein-regulating mechanism

PCI-32765 is highly active and well tolerated in patients with CLL

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

Ixabepilone-sunitinib combination holds potential against chemotherapy-resistant ovarian cancer

Study shows new biochemical disturbances in the brains of children with ADHD

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

Lapatinib could extend survival in women with Her2-positive breast cancer

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Scientists identify factors that lead to concomitant tumor resistance

Health supplement hope for child muscle disease

NCCN ORP to evaluate clinical effectiveness of Boehringer Ingelheim's Afatinib in solid tumors

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

Fat-rich 'western diet' fuels cardiovascular disease, type 2 diabetes and obesity

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News